Clinical Trial Update: Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Long-term safety findings from a Phase 3 trial evaluating vildagliptin 100 mg once daily in patients with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED